Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative

doi:10.3748/wjg.v26.i19.2416

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9340)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

542

WORD

197

HTML

5224

Figures (1-2)

331

Tables (1-3)

310

Sum=6604

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

806

Download

1930

Sum=2736

May 21, 2020 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. May 21, 2020; 26(19): 2416-2426
Published online May 21, 2020. doi: 10.3748/wjg.v26.i19.2416

Table 1 Baseline characteristics of nonalcoholic fatty liver disease patients and comparison between low- and high-cardiovascular disease-risk groups

Characteristics	Total	Low risk	High risk	P value
median (IQR); n (%)	n = 1122	n = 800	n = 322	N/A
Age in yr	53 (44-60)	49 (41-55)	63 (59-67)	< 0.001
Female	532 (47.4%)	391 (48.9%)	141 (43.8%)	0.12
Weight (kg)	76 (66-87)	77 (67-88)	74 (65-84)	0.002
Height (m)	1.63 (1.56-1.7)	1.64 (1.57-1.71)	1.61 (1.55-1.67)	< 0.001
BMI (kg/m²)	28.36 (25.8-31.47)	28.38 (25.84-31.45)	28.31 (25.68-31.65)	0.572
Waist circumference (cm)	96.5 (89-104)	96 (88.3-103.5)	98 (90-106)	0.017
Hip circumference (cm)	103 (97-109)	103 (97-109)	102.5 (96-109)	0.502
Ethnic origin: Chinese	492 (43.9%)	405 (50.6%)	87 (27%)	< 0.001
Diabetes	642 (57.2%)	365 (45.6%)	277 (86%)	< 0.001
Hypertension	639 (57%)	400 (50.1%)	239 (74.5%)	< 0.001
Dyslipidemia	635 (56.6%)	419 (66.6%)	216 (75.5%)	0.007
Albumin (g/L)	44 (41-46)	44 (42-46)	42.5 (39-45)	< 0.001
ALT (U/L)	63 (41-100)	69 (43-106)	49 (30-82)	< 0.001
AST (U/L)	40 (41-61)	41 (27-61)	39 (28-62)	0.98
ALP (U/L)	75 (41-96)	76 (63-95.5)	74 (58-96.5)	0.63
GGT (U/L)	64 (41-105)	66 (38-103)	60 (37-113)	0.563
HbA1c (%)	6.6 (41-7.5)	6.2 (5.6-7.2)	7.2 (6-7.9)	< 0.001
Total cholesterol (mmol/L)	4.8 (41-5.5)	4.9 (4.3-5.6)	4.4 (3-5.113)	< 0.001
LDL cholesterol (mmol/L)	2.8 (41-3.4)	2.95 (2.4-3.56)	2.465 (1-3.1)	< 0.001
HDL cholesterol (mmol/L)	1.2 (41-1.4)	1.2 (1-1.4)	1.14 (0-1.37)	0.002
Triglycerides (mmol/L)	1.6 (41-2.1)	1.6 (1.151-2.1)	1.6 (1-2.13)	0.411
Hemoglobin (g/dL)	14.0 (41-15.2)	14.2 (13.3-15.3)	13.6 (12-14.6)	< 0.001
Platelet (10⁹/L)	243 (41-289)	249 (205-294.25)	229 (189-280)	< 0.001
WBC (10⁹/L)	7.1 (41-8.4)	7.03 (5.8-8.39)	7.25 (5-8.4)	0.28
NAFLD Activity Score¹	4 (3-5)	4 (3-5)	4 (3-5)	0.684
Significant fibrosis (≥ F2): histopathology	464 (41.4%)	286 (35.9%)	178 (55.3%)	< 0.001
Advanced fibrosis (≥ F3): histopathology	314 (28%)	173 (21.7%)	141 (43.8%)	< 0.001
Cirrhosis	109 (9.7%)	50 (6.3%)	59 (18.3%)	< 0.001
CAP	325 (294-349)	323 (297-349)	326 (286-349)	0.979
Liver stiffness measurement: TE (kPa)	9.3 (6.7-13.9)	8.6 (6.3-12)	11 (7.6-15.8)	< 0.001
10-year CVD risk by QRISK2 (%)	5.9 (2.6-10.9)	3.8 (1.9-6.4)	14.7 (12-19.3)	< 0.001
Relative risk of 10-year CVD risk	1.65 (1.13-2.2)	1.51 (1.06-2.26)	1.76 (1-2.08)	< 0.001

N/A: Not applicable; NAFLD: Nonalcoholic fatty liver disease; CVD: Cardiovascular disease; BMI: Body mass index; GGT: Gamma-glutamyl transferase; AST: Aspartate transaminase; ALT: Alanine transaminase; ALP: Alkaline phosphatase; CAP: Controlled attenuation parameter; TE: Transient elastography; WBC: White blood cell; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; IQR: Interquartile range; F: Fibrosis stage.

¹Commonly referred to as NAS.

Citation: Pitisuttithum P, Chan WK, Goh GBB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Dan YY, Imajo K, Nakajima A, Ho KY, Goh KL, Wong VWS, Treeprasertsuk S. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. World J Gastroenterol 2020; 26(19): 2416-2426
URL: https://www.wjgnet.com/1007-9327/full/v26/i19/2416.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i19.2416